Global Retinal Drugs Market 2017-2021

網膜症治療薬の世界市場2017-2021

◆タイトル:Global Retinal Drugs Market 2017-2021
◆商品コード: IRTNTR13389
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年7月12日
◆ページ数:88
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・ヘルスケア
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥374,500見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥535,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、網膜症治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、バリューチェーン分析、疾患概要、網膜症治療薬の世界市場規模及び予測、種類別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況などの情報をお届けいたします。

眼病の大半は、治療が不要か最小限で済む軽微なものですが、中には専門医による治療が必要なものもあり、放置しておけば失明につながる恐れもあります。具体的には、網膜症や緑内障、ドライアイ、目の感染症/炎症、アレルギー性疾患などが挙げられます。特に網膜疾患向け治療薬は、眼病治療薬市場で最大のシェアを占めていますTechnavio社は網膜症治療薬の世界市場が2017-2021年期間中に年平均0.1166成長すると予測しています。当レポート上に記載されている主な企業は• Bayer• F. Hoffmann-La Roche• Novartis• Regeneron等です。

・エグゼクティブサマリー
・網膜症治療薬の世界市場:市場概観
・網膜症治療薬の世界市場:業界の構造分析
・網膜症治療薬の世界市場:バリューチェーン分析
・網膜症治療薬の世界市場:疾患概要
・網膜症治療薬の世界市場:市場規模及び予測
・網膜症治療薬の世界市場:種類別分析
・網膜症治療薬の世界市場:地域別分析
・網膜症治療薬の世界市場:アジア市場規模
・網膜症治療薬の世界市場:アメリカ市場規模
・網膜症治療薬の世界市場:ヨーロッパ市場規模
・網膜症治療薬の世界市場:成長要因
・網膜症治療薬の世界市場:課題
・網膜症治療薬の世界市場:市場動向
・網膜症治療薬の世界市場:競争状況
...

※上記の和訳は最新内容ではない場合があります。下記の英文概要・目次が最新版です。

About Retinal DrugsOphthalmic disorders largely consist of minor disorders that need minimal or no treatment, however, few other disorders become critical in nature and need specialist care. A delay in treatment in case of critical disorders may even lead to vision loss.
Retinal disorders, glaucoma, dry-eye, infection/inflammation in the eyes, and allergic/otic problems are the major ophthalmic disorders. The retinal drugs market holds the largest share of the global ophthalmic disorder treatment market, followed by glaucoma treatment drugs market. The global retinal drugs market is expected to grow with a high CAGR of 11.66% due to the high demand of age-related macular degeneration (AMD) drugs and diabetic eye disease drugs. This is due to the rising geriatric population and an increase in the population with diabetes. Also, countries across the globe are investing significantly in the healthcare sector. This has, in turn, increased awareness and diagnosis rate of the disease.

Technavio’s analysts forecast the global retinal drugs market to grow at a CAGR of 11.66% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global retinal drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs in retinal disorders market.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Retinal Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Bayer
• F. Hoffmann-La Roche
• Novartis
• Regeneron

[Other prominent vendors]
• Merck
• Shire
• Teva Pharmaceutical
• ThromboGenics

[Market driver]
• Rising geriatric population and corresponding increase in patient pool
• For a full, detailed list, view our report

[Market challenge]
• Shortage of trained professionals
• For a full, detailed list, view our report

[Market trend]
• Rising use of combination therapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline

PART 05: Market landscape
• Market overview
• Five forces analysis

PART 06: Pipeline landscape

PART 07: Segmentation by type of disease
• Global MD drugs market
• Global diabetic eye disease drugs market
• Global other retinal drugs market

PART 08: Market segmentation by ROA
• IV
• Intravitreal

PART 09: Geographical segmentation
• Retinal drugs market in Americas
• Retinal drugs market in EMEA
• Retinal drugs market in APAC
• Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends

PART 12: Vendor landscape
• Competitive scenario
• Bayer
• Novartis
• Regeneron
• F. Hoffmann-La Roche
• Other prominent vendors

PART 13: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Market overview of global ophthalmic drugs market
Exhibit 02: Value chain analysis for global ophthalmic drugs market
Exhibit 03: Types of AMD
Exhibit 04: Stages of AMD
Exhibit 05: Symptoms associated with AMD
Exhibit 06: Diagnosis and management
Exhibit 07: Diabetic eye diseases affecting retina
Exhibit 08: Diagnosis and management of diabetic eye diseases
Exhibit 09: Global retinal drugs market: Snapshot
Exhibit 10: Global retinal drugs market 2016-2021 ($ millions)
Exhibit 11: Opportunity analysis of global retinal drugs market
Exhibit 12: Five forces analysis
Exhibit 13: Pipeline landscape of vendors
Exhibit 14: Key clinical trials
Exhibit 15: Global retinal drugs market by type of disease
Exhibit 16: Global retinal drugs market share by type of disease 2016 and 2021
Exhibit 17: Global MD drugs market 2016-2021 ($ millions)
Exhibit 18: Global MD drugs market: Snapshot
Exhibit 19: Major approved drugs for MD
Exhibit 20: Global MD drugs market by type of AMD 2016
Exhibit 21: Global diabetic eye disease drugs market 2016-2021 ($ millions)
Exhibit 22: Global diabetic eye disease drugs market: Snapshot
Exhibit 23: Major types of diabetic eye diseases affecting retina
Exhibit 24: Diabetic retinopathy: Disease overview
Exhibit 25: Global other retinal drugs market 2016-2021 ($ millions)
Exhibit 26: Global retinal drugs market by ROA 2016
Exhibit 27: Global retinal drugs market by geography 2016 and 2021
Exhibit 28: Global retinal drugs market by geography 2016-2021 ($ millions)
Exhibit 29: Market scenario in Americas
Exhibit 30: Retinal drugs market in Americas 2016-2021 ($ millions)
Exhibit 31: Estimated vision problems in US 2020
Exhibit 32: Market scenario EMEA
Exhibit 33: Retinal drugs market in EMEA 2016-2021 ($ millions)
Exhibit 34: Market scenario APAC
Exhibit 35: Retinal drugs market in APAC 2016-2021 ($ millions)
Exhibit 36: Asian countries with highest diabetic populations
Exhibit 37: Population in age group 60 and above by region 2015 and 2050
Exhibit 38: Major complications associated with diabetes
Exhibit 39: New cases of diabetes 2040
Exhibit 40: Biosimilars in ophthalmic drugs market
Exhibit 41: Competitive structure analysis of global retinal drugs market 2016
Exhibit 42: Strategic success factors of companies in global retinal drugs market
Exhibit 43: Bayer: Key highlights
Exhibit 44: Bayer: Strength assessment
Exhibit 45: Bayer: Strategy assessment
Exhibit 46: Bayer: Opportunity assessment
Exhibit 47: Novartis: Key highlights
Exhibit 48: Novartis: Strength assessment
Exhibit 49: Novartis: Strategy assessment
Exhibit 50: Novartis: Opportunity assessment
Exhibit 51: Regeneron: Key highlights
Exhibit 52: Regeneron: Strength assessment
Exhibit 53: Regeneron: Strategy assessment
Exhibit 54: Regeneron: Opportunity assessment
Exhibit 55: F. Hoffmann-La Roche: Key highlights
Exhibit 56: F. Hoffmann-La Roche: Strength assessment
Exhibit 57: F. Hoffmann-La Roche: Strategy assessment
Exhibit 58: F. Hoffmann-La Roche: Opportunity assessment



【掲載企業】

Bayer, F. Hoffmann-La Roche, Novartis, and Regeneron.
Merck, Shire, Teva Pharmaceutical, and ThromboGenics.


【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[網膜症治療薬の世界市場2017-2021]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆